Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?

Moccia, Marcello; Picillo, Marina; Erro, Roberto; Longo, Katia; Amboni, Marianna; Santangelo, Gabriella; Spina, Emanuele; Rosa, Anna De; Michele, Giuseppe De; Santoro, Lucio; Barone, Paolo; Pellecchia, Maria Teresa

doi:10.1016/j.parkreldis.2014.03.016

Cited by 38 publications

(57 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of non-motor symptoms, our study also showed a negative relationship between serum UA levels and depression score but not with cognitive score, similar to the recent study in de novo adjusted PD models [7,9]. These observations suggest that UA not only has a protective effect against dopaminergic cell loss but also against non-dopaminergic cells such as serotonergic neurons [5].…”

Section: Discussionsupporting

confidence: 90%

“…A reduction in the glomerular filtration rate can increase the level of serum UA and a recent meta-analysis indicated that low serum UA levels are associated with an increased risk and progression of PD [6]. A recent study also showed a negative relationship between UA levels and non-motor symptoms in de novo PD patients [7]. Although a relationship between UA levels and PD has been demonstrated, the association of UA and motor subtypes of PD has not been studied.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between serum uric acid and motor subtypes of Parkinson’s disease

Lolekha

Wongwan

Kulkantrakorn

2015

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Association between serum uric acid and motor subtypes of Parkinson’s disease

Lolekha

Wongwan

Kulkantrakorn

2015

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…Thus, UA may play a different role in patients than in healthy individuals. In contrast, in drug‐naïve PD patients, lower UA levels have been associated with cardiovascular domains, as evaluated by NMSQuest (Moccia et al., 2014). Pan et al.…”

Section: Discussionmentioning

confidence: 99%

“…Moccia et al. (2014) reported that early‐stage, drug‐naïve PD patients with lower serum UA levels had higher scores in the attention/memory, cardiovascular, and sleep domains, as evaluated by NMSQuest. In MSA patients, no correlation has been found between serum UA levels at the initial visit and the mean rate of annual changes in the Unified MSA Rating Scale (Cao et al., 2013).…”

Section: Introductionmentioning

confidence: 99%

Serum uric acid levels in Parkinson's disease and related disorders

et al. 2016

View full text Add to dashboard Cite

ObjectiveSerum uric acid (UA) levels are reported to be decreased in patients with Parkinson's disease (PD) and multiple system atrophy (MSA). However, clinical correlates of serum UA levels are still unclear in PD‐related disorders. We conducted a cross‐sectional study to evaluate the associations between serum UA levels and disease duration, disease severity, and motor function among PD, MSA, and progressive supranuclear palsy (PSP) patients.MethodsA total of 100 patients with PD, 42 patients with MSA, 30 patients with PSP, and 100 controls were included in this study. Serum UA levels were determined, and associations among serum UA levels and disease duration, disease severity, and motor function in PD, PSP, and MSA patients were evaluated.ResultsSerum UA levels were significantly lower in male PD, MSA, and PSP patients compared with the controls, but not in female patients. Serum UA levels were negatively correlated with disease duration and severity in MSA and PSP patients, but no correlations were observed in PD patients. The serum UA levels were significantly decreased in the tauopathy group (PSP patients) compared with the synucleinopathy group (PD and MSA patients) after adjusting for age, gender, and body mass index.ConclusionWe found decreased serum UA levels in male patients with PD‐related disorders (PD, MSA, and PSP) compared with male controls, and significant correlations between serum UA levels and disease severity in MSA and PSP patients.

show abstract

“…In detail, UA levels have been associated with specific NMS, such as attention/ memory, depression/anxiety, and cardiovascular. 117,120,121 The association with the impairment of attention/memory domains seems particularly promising since confirmed by different studies exploring cognitive function with comprehensive neuropsychological batteries. 122,123 Furthermore, a recent Phase 2 trial on the use of inosine in PD, a precursor of UA, showed a possible association between increased UA levels and mood disorders assessed with the Geriatric Depression Scale.…”

Section: Oxidative Stressmentioning

confidence: 93%